Most of the people who died of smallpox in monkeys were Africans. There are two different strains of the disease, a more lethal strain circulating in the Democratic Republic of the Congo and neighboring countries, and a less virulent version in West Africa, currently seen in low-income countries. high input. Although deaths from monkeypox are rare, the risk of death is highest in children and pregnant women, and the disease causes extreme pain to anyone infected.
Everything you need to know about Monkey Smallpox Virus
What is monkeypox? Monkeypox is a virus similar to smallpox, but the symptoms are less severe. It was discovered in 1958, after an outbreak of disease in monkeys kept for research. The virus is mainly found in parts of Central and West Africa, but it has recently spread to dozens of countries and infected tens of thousands of people, overwhelmingly those who have sex. homosexuality.
The rapid spread of the disease to high-income countries, which began four months ago, has sparked a scramble for a vaccine. Although there is no vaccine specifically for monkeypox, data from trials with non-human primates suggest that vaccines against smallpox virus are closely related. can also prevent transmission of this virus. The focus is on the Jynneos smallpox vaccine, made by the Danish company Bavarian-Nordic, which is the easiest to use of the smallpox vaccines and has the lowest number of side effects.
Bavarian-Nordic has about 16 million doses of vaccines, most of which are owned or contracted by the United States, which has contributed more than $1 billion to vaccine development as a defense strategy. after 9/11 when officials were concerned about a possible smallpox. used as a biological weapon. Those US doses are seen as a defense stockpile and are in bulk drug form, not bottled vaccine, which has slowed distribution. The remaining 1 million were quickly purchased by Canada, Australia and European countries starting in May.
To date, no doses have been purchased or ordered for African countries. A clinical trial of the Jynneos vaccine led by the National Institutes of Health is starting in Congo, but that country does not have the vaccine available for healthcare workers or those in contact with people who are sick. .
James Krellenstein, a founder of PrEP4All, an advocacy group for drug access. “This is the single most important step anyone can take to help bring this outbreak under control globally.”
None of the 7 million doses sent for bottling to date have been designated for global reach.
An analysis by advocacy group Public Citizen estimates that high-income countries that have used the Jynneos vaccine are paying $110 per dose. Paul Chaplin, president of Bavarian-Nordic, said in an earnings call last month that the vaccine has one price point in all markets, which will only be discounted to bulk buyers.